Leuven (BELGIUM) – September 8, 2010 - TiGenix (NYSE EURONEXT: TIG)
announces final closing of EUR 4.1 million seed-financing for Arcarios spin-out.
TiGenix recently announced the first closing of a seed-financing round for Acarios, a spin-
out established jointly with Netherlands-based Therosteon (press release of 25/08/2010).
Today, we are happy to announce that LRM has joined the existing international investor
syndicate to bring the total funds raised to EUR 4.1 million. The seed financing round was
led by BioGeneration Ventures. Other investors include Erasmus MC Biomedical Fund,
Gemma Frisius Fund, CD3, Baekeland Fund II, Credit Agricole and VINNOF.
TiGenix has a significant equity stake in Arcarios (below the consolidation threshold) and is
the largest shareholder of the company. TiGenix also retains certain rights to drug
candidates developed by Arcarios for ex vivo applications and the local treatment of arthritic
For more information, please contact:
Gil Beyen Kris Motmans
Chief Executive Officer, TiGenix Corporate Development and Communication
T: +32 16 39 60 60
Chief Executive Officer, Arcarios
T: +32 620 543 382
email@example.com TiGenix NV • Romeinse straat 12 bus 2, 3001 Leuven, Belgium • 0471.340.123 RPR Leuven • tel +32 (16) 39 60 60
Based in Leuven, Belgium, TiGenix NV (NYSE Euronext Brussels: TIG) is a public biomedical
company that focuses on ‘Regenerating Motion’. The company is exploiting the power of
Regenerative Medicine to develop durable treatments, validated through controlled clinical trials, for
damaged and diseased skeletal tissues. TiGenix now has two products approved for marketing and
sales in Europe:
ChondroCelect®, the company’s lead product for cartilage regeneration in the knee, is the first cell-
based product that successfully completed the entire development track from research, over clinical
development to central European registration as a medicinal product. ChondroCelect consists of
characterized cultured chondrocytes derived from the patient’s own cartilage and is used for
autologous chondrocyte implantation (ACI), a surgical procedure to treat cartilage defects.
ChondroCelect received European Marketing Authorization as the first Advanced Therapy Medicinal
ChondroMimetic™ is an off-the-shelf, collagen based implant for the treatment of small
osteochondral (cartilage and underlying bone) defects. ChondroMimetic received CE-mark approval
for the treatment of small chondral and subchondral lesions. It will be marketed as a procedure pack
with the collagen implant preloaded in an accurate, easy to use delivery device.
The company exploits a proprietary (stem) cell and biomaterials platform, which will continue to
generate candidate products that address specific musculoskeletal problems.
With a fully operational sales team in place, TiGenix is ready for commercial expansion and
reinforcement of its leading position in Europe in the regenerative medicine field.
Based in Rotterdam and Diepenbeek, Arcarios is a drug development company dedicated to the
discovery and development of innovative products that target bone and joint diseases, indications of
unmet medical need and significant commercial potential. The Company combines Benelux’ best
science in the field of bone and joint biology and was formed by the merger of Therosteon and a
spin-out of TiGenix NV, Belgium. The founding scientists of Arcarios have developed an innovative
pipeline of proprietary disease modifying therapeutics for bone and joint diseases, based on
proprietary platform technologies and covered by a broad portfolio of granted and pending patents.
Arcarios aims at bringing at least one of its two lead programs into clinic within the coming years
followed by a pipeline of preclinical drug candidates.
LRM is a profit-driven investor that offers entrepreneurs a unique combination of venture capital and
real estate. LRM's activities contribute to the economic development and the general employment in
Limburg province. They are oriented towards all sectors and companies, from start-ups to growing
SMEs to major businesses. Today, LRM is active in five domains: ICT & Media, Life Sciences,
Cleantech & Energy, SMEs & Large enterprises.